Cancer Stem Cell News Volume 11.11 | Mar 23 2022

    By
    Justin.choi
    -
    0
    214







    2022-03-23 | CSCN 11.11


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.11 – 23 March, 2022
    TOP STORY

    A Novel HIF-2α Targeted Inhibitor Suppresses Hypoxia-Induced Breast Cancer Stemness via SOD2-mtROS-PDI/GPR78-UPRER Axis
    Scientists illustrated that HIF-2α, but not HIF-1α, induced stemness in breast cancer cells under hypoxia through SOD2-mtROS-PDI/GRP78-UPRER pathway, linking mitochondrial metabolic state to endoplasmic reticulum (ER) response via mitochondrial reactive oxygen species (mtROS) level.
    [Cell Death & Differentiation]
    Full Article
    Join us in our mission to advance the pursuit of scientific knowledge by supplying high-quality, innovative reagents, tools and services that enable life science research.
    PUBLICATIONSRanked by the impact factor of the journal

    Hypoxia-Induced GLT8D1 Promotes Glioma Stem Cell Maintenance by Inhibiting CD133 Degradation through N-linked Glycosylation
    Depletion of glycosyltransferase 8 domain containing 1 (GLT8D1) inhibited self-renewal of glioma stem cells in vitro and repressed tumor growth in glioma mouse models.
    [Cell Death & Differentiation]
    Abstract

    DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
    The authors tested if inhibition of DOT1L, an epigenetic regulator of normal tissue stem/progenitor populations, would target triple-negative breast cancers stem cells.
    [Clinical Cancer Research]
    Abstract

    A Self-Assembled Leucine Polymer Sensitizes Leukemic Stem Cells to Chemotherapy by Inhibiting Autophagy in Acute Myeloid Leukemia
    Investigators found that acute myeloid leukemia (AML) cells obtained from relapsed patients had increased autophagy levels than de novo AML cells.
    [Haematologica]
    Abstract

    UPF1 Contributes to the Maintenance of Endometrial Cancer Stem Cell Phenotype by Stabilizing LINC00963
    Scientists showed that the expression of up-frameshift mutant 1 (UPF1) was upregulated in endometrial cancer tissues and endometrial CSCs and correlated with poor clinicopathological characteristics.
    [Cell Death & Disease]
    Full Article

    A Chemical Probe Inhibitor Targeting STAT1 Restricts Cancer Stem Cell Traits and Angiogenesis in Colorectal Cancer
    4’,5,7-trihydroxyisoflavone probe was a new chemical probe inhibitor of signal transducer and activator of transcription 1 (STAT1) that reduced stemness and angiogenesis in colorectal cancer.
    [Journal of Biomedical Science]
    Full Article

    Tumor-Associated Macrophage Derived IL-6 Enriches Cancer Stem Cell Population and Promotes Breast Tumor Progression via Stat-3 Pathway
    Researchers reported that macrophages, upon interaction with breast cancer cells, activated tumor promoting functions and exhibited differential expression of various proteins as shown by secretome analysis using proteomics studies.
    [Cancer Cell International]
    Full Article

    Claudin1 Decrease Induced by 1,25-Dihydroxy-Vitamin D3 Potentiates Gefitinib Resistance Therapy through Inhibiting AKT Activation-Mediated Cancer Stem-Like Properties in NSCLC Cells
    Investigators performed GEO dataset analysis and identified that claudin1 was a critical regulator of epidermal growth factor receptor tyrosine kinase inhibitors resistance in non-small cell lung cancer (NSCLC) cells.
    [Cell Death Discovery]
    Full Article

    LncRNA GAS5 Enhances Tumor Stem Cell-Like Medicated Sensitivity of Paclitaxel and Inhibits Epithelial-to-Mesenchymal Transition by Targeting the miR-18a-5p/STK4 Pathway in Prostate Cancer
    Scientists identified downregulated long noncoding RNA (lncRNA) growth arrest-specific 5 (GAS5) in prostate cancer that was associated with metastasis and paclitaxel resistance.
    [Asian Journal of Andrology]
    Abstract

    LCOR Mediates Interferon-Independent Tumor Immunogenicity and Responsiveness to Immune-Checkpoint Blockade in Triple-Negative Breast Cancer
    Researchers showed that immune-checkpoint blockade (ICB) therapy selected for ligand-dependent corepressor (LCOR) low CSCs with reduced antigen processing/presentation machinery driving immune escape and ICB resistance in triple-negative breast cancer.
    [Nature Cancer]
    Full Article
    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    REVIEWS

    Single-Cell Analysis of Circulating Tumor Cells: Enabling Technologies and Clinical Applications
    Scientists highlight the biological features, clinical application, and the therapeutic potential of circulating tumor cells (CTCs) and CTC clusters using single-cell analysis platforms for cancer management.
    [Trends in Biotechnology]
    Abstract

    Understanding Autophagy Role in Cancer Stem Cell Development
    Investigators suggest that hypoxia-induced autophagy and CSCs proliferation should be elucidated in order to find a novel cure to defeat cancer cells.
    [Molecular Biology Reports]
    Abstract

    Glycosphingolipids in Human Embryonic Stem Cells and Breast Cancer Stem Cells, and Potential Cancer Therapy Strategies Based on Their Structures and Functions
    The authors indicate that GD3 synthase contributes to gefitinib resistance in epidermal growth factor receptor-positive breast cancer cells, and is a potentially useful therapeutic target in drug-resistant breast cancers.
    [Glycoconjugate Journal]
    Abstract
    INDUSTRY AND POLICY NEWS

    AIM ImmunoTech Receives IND Clearance from the US FDA to Advance its Phase II Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
    AIM ImmunoTech, Inc. announced it has received notification from the FDA that the FDA’s Clinical Hold on AIM’s investigational new drug (IND) application for a Phase II study of Ampligen as a therapy for locally advanced pancreatic cancer has been lifted and the company may proceed with the study.
    [AIM ImmunoTech Inc.]
    Press Release

    Wugen Announces First Patient Dosed in Phase I/II Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL
    Wugen, Inc. announced that the first patient has been dosed in a Phase I/II trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).
    [Wugen, Inc.]
    Press Release
    FEATURED EVENT

    AACR Annual Meeting 2022
    April 8-13, 2022
    New Orleans, Louisiana, United States

    > See All Events
    JOB OPPORTUNITIES

    Postdoctoral Scientist – Translational Oncogenomics Group
    CRUK Manchester Institute – Manchester, United Kingdom

    Principal Scientific Researcher – Cell and Tissue Genomics
    Genentech, Inc. – South San Francisco, California, United States

    Senior Associate Scientist – Biology
    Gilead Sciences – Foster City, California, United States

    Postdoctoral Scholar – Cancer Cell Identity
    Oregon Health and Science University – Portland, Oregon, United States

    PhD Scientist – Oncology
    University of Virginia School of Medicine – Charlottesville, Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter